Cart
sales@molnova.com
Ifidancitinib
CAS No. 1236667-40-5
Ifidancitinib( —— )
Catalog No. M35053 CAS No. 1236667-40-5
Ifidancitinib (ATI-50002) is a specific JAK kinase 1/3 inhibitor that induces hair growth in AA-affected C3H/HeJ mice.Ifidancitinib can be used to study autoimmune diseases.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 226 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameIfidancitinib
-
NoteResearch use only, not for human use.
-
Brief DescriptionIfidancitinib (ATI-50002) is a specific JAK kinase 1/3 inhibitor that induces hair growth in AA-affected C3H/HeJ mice.Ifidancitinib can be used to study autoimmune diseases.
-
DescriptionIfidancitinib (ATI-50002) is a potent and selective inhibitor of JAK kinases 1/3. Ifidancitinib can be used in studies of allergies, asthma and autoimmune diseases.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetJAK
-
RecptorJAK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1236667-40-5
-
Formula Weight395.39
-
Molecular FormulaC20H18FN5O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 62.5 mg/mL (158.07 mM; Ultrasonic )
-
SMILESCOc1cc(Nc2ncc(C)c(Nc3ccc4oc(=O)[nH]c4c3)n2)cc(C)c1F
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Li, Hui; Heckrodt, Thilo J.; Chen, Yan; Mcmurtrie, Darren John; Taylor, Vanessa; Singh, Rajinder; Ding, Pingyu; Yen, Rose.Preparation of phenylaminopyrimidinylaminooxobenzooxazole derivatives for use as JAK kinase inhibitors. WO2012015972A1
molnova catalog
related products
-
Levofloxacin
Levofloxacin is a broad-spectrum antibiotic topoisomerase II and topoisomerase IV inhibitor, used to treat respiratory, urinary tract, gastrointestinal, and abdominal infections.
-
JAK-IN-5 hydrochlori...
JAK-IN-5 hydrochloride is an inhibitor of JAK.
-
BMS-986165
BMS-986165 is differentiated from previous JAK inhibitors due its unique ability to selectively bind to the pseudokinase (JH2) domain of TYK2 and inhibit its function through an allosteric mechanism.
